Sfoglia per AUTORE
AIETA M
Collezione AOU San Luigi di Orbassano

  

Items : 4

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18.

2016
AOU San Luigi di Orbassano

Veccia A; Caffo O; De Giorgi U; Di Lorenzo G; Ortega C; Scognamiglio F; Aieta M; Facchini G; Mansueto G; Mattioli R; Procopio G; Zagonel V; D'Angelo A; Spizzo G; Bortolus R; Donini M; Lo Re G; Massari F; Vicario G; Zucali PA; Alesini D; Bonetti A; Mucciarini C; Nicodemo M; Berruti A; Fratino L; Lodde M; Messina C; Perin A; et alii...

Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. in Urologic oncology / Urol Oncol. 2015 Jun;33(6):265.e15-21. doi: 10.1016/j.urolonc.2015.02.016. Epub 2015 Apr 20.

2015
AOU San Luigi di Orbassano

Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; et alii...

Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. in European urology / Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25.

2015
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; et alii...

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7. Epub 2014 May 13.

2014
AOU San Luigi di Orbassano

Gregorc V; Novello S; Lazzari C; Barni S; Aieta M; Mencoboni M; Grossi F; De Pas T; de Marinis F; Bearz A; Floriani I; Torri V; Bulotta A; Cattaneo A; Grigorieva J; Tsypin M; Roder J; Doglioni C; Levra MG; Petrelli F; Foti S; Viganò M; Bachi A; Roder H;